Trials / Active Not Recruiting
Active Not RecruitingNCT03215095
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab (Medi4736) | durvalumab 1500 mg IV every 4 weeks |
| RADIATION | Radioiodine (RAI) | 100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days. |
Timeline
- Start date
- 2017-07-10
- Primary completion
- 2023-02-06
- Completion
- 2026-07-01
- First posted
- 2017-07-12
- Last updated
- 2025-07-17
- Results posted
- 2024-03-22
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03215095. Inclusion in this directory is not an endorsement.